Resveratrol vs Pterostilbene

Resveratrol and pterostilbene are the two most talked-about stilbenes in longevity supplementation, and they are frequently sold as interchangeable. They are not. Pterostilbene is chemically a close cousin of resveratrol — a "dimethylated" version — and that small structural change produces a dramatically different absorption profile, a different side effect signal, and a very different regulatory status in the United Kingdom.

For where both sit among the alternatives, start with our pillar guide to longevity supplements and the wider anti-ageing and longevity range. On the resveratrol side, you can buy resveratrol supplements including Welzo Ultra Purity Trans-Resveratrol. Both compounds also sit inside the broader NAD+ conversation — see our NMN benefits, side effects and dosage pillar and the NMN supplement range.

This guide compares resveratrol vs pterostilbene across the things that actually determine whether a supplement is worth your money: bioavailability, mechanism, the quality of human clinical evidence, safety signals, UK legality and cost. It is written for readers who already understand that a compelling mouse study is not the same thing as a proven human benefit.

What are resveratrol and pterostilbene?

Both molecules belong to a family of plant compounds called stilbenes. Plants make them defensively, in response to UV light, injury and fungal attack. Both share the same 6–2–6 carbon skeleton: two phenyl rings joined by a double-bonded ethylene bridge, and both are supplied predominantly in the more biologically active trans form.

Resveratrol

Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is found in red grape skins, red wine, peanuts and some berries. Commercial supplements almost never come from wine — a glass of red contains only single-digit milligram amounts at best. Supplement-grade material is usually extracted from Japanese knotweed (Polygonum cuspidatum) or produced by yeast fermentation.

It became famous in the mid-2000s when it was proposed as a caloric-restriction mimetic and sirtuin activator. Two decades on, the picture is considerably more nuanced, which we cover in detail in Does resveratrol actually work?

Pterostilbene

Pterostilbene (3,5-dimethoxy-4′-hydroxy-trans-stilbene) occurs naturally in blueberries, grapes and the heartwood of Pterocarpus trees. Chemically it is resveratrol with two of the three hydroxyl (−OH) groups replaced by methoxy (−OCH₃) groups.

The structural difference that changes everything

Those two methoxy groups do three things. They make the molecule more lipophilic (fat-soluble), which improves passage across cell membranes and the blood–brain barrier. They reduce the number of sites available for rapid Phase II conjugation in the gut wall and liver, which is the main reason resveratrol disappears from circulation so quickly. And they increase metabolic stability, so plasma levels stay higher for longer.

Resveratrol vs pterostilbene: full comparison table

Bioavailability: the single biggest difference

What the pharmacokinetic data actually shows

The most widely cited comparison is a US National Cancer Institute–funded study by Kapetanovic and colleagues, published in Cancer Chemotherapy and Pharmacology in 2011. Rats received equimolar oral doses of resveratrol (50 or 150 mg/kg/day) or pterostilbene (56 or 168 mg/kg/day) for 14 consecutive days, with additional intravenous arms so that absolute bioavailability could be calculated.

The headline result: resveratrol was approximately 20% bioavailable and pterostilbene approximately 80% bioavailable. Plasma levels of pterostilbene and its sulfate metabolite were markedly higher than the equivalent resveratrol species, and total body clearance of resveratrol was substantially faster.

The reason lies in Phase II metabolism. Resveratrol's three hydroxyl groups are ideal substrates for sulfotransferases and UDP-glucuronosyltransferases in the intestinal wall and liver. It is absorbed reasonably well, but most of it is conjugated before it reaches systemic circulation. As the Linus Pauling Institute's Micronutrient Information Center summarises, free resveratrol is present in human plasma only in trace amounts after oral dosing, with the overwhelming majority circulating as sulfate and glucuronide conjugates.

Why methoxy groups matter so much

Each methoxy substitution removes a conjugation site and adds lipophilicity. Pterostilbene has only one free hydroxyl group left, so there is far less for Phase II enzymes to grab. The practical consequence is that a smaller pterostilbene dose can deliver more circulating active compound than a much larger resveratrol dose.

Does better bioavailability mean better results?

Not automatically, and this is where a great deal of supplement marketing overreaches. Three caveats matter:

• The 20% vs 80% figures come from rats, not humans. Direct equimolar human comparisons are scarce.
• Some of resveratrol's conjugated metabolites may be biologically relevant, acting as a reservoir that is deconjugated inside tissues. Low free-parent plasma levels are not automatically the same as low activity.
• Bioavailability is a surrogate marker. What matters clinically is the endpoint — blood pressure, cognition, glycaemic control — and on those endpoints resveratrol currently has more human data. We discuss this pattern of surrogate-marker overclaiming across the category in longevity supplements that don't work.

How each compound works in the body

Both stilbenes influence overlapping nutrient-sensing pathways. Mapping them against the recognised hallmarks of ageing helps explain why they attract longevity interest — and why mechanism alone is never sufficient evidence.

SIRT1 and the sirtuin story

Resveratrol's fame rests on in vitro work showing it activates sirtuin 1 (SIRT1), an NAD⁺-dependent deacetylase involved in stress resistance and metabolic regulation. That finding was later contested: much of the apparent activation appeared to be an artefact of the fluorophore-tagged substrate used in the original assays, and direct activation in physiological conditions is still debated. Resveratrol almost certainly acts partly indirectly, via AMPK and downstream PGC-1α.

Because sirtuins consume NAD⁺ as a cofactor, stilbenes are commonly paired with NAD⁺ precursors. Our NAD supplement guide explains that relationship in detail.

AMPK and metabolic signalling

Both compounds activate AMP-activated protein kinase, the cell's low-energy sensor. AMPK activation shifts cells toward catabolic, energy-generating processes and away from anabolic ones, and is the same pathway targeted by exercise, fasting and metformin. This is the mechanistic basis for the "calorie-restriction mimetic" framing.

PPAR-α and the brain

This is where pterostilbene diverges most clearly. A 2012 study in Neurobiology of Aging compared diet-achievable doses of resveratrol and pterostilbene in SAMP8 mice, a model of accelerated ageing. At equivalent doses, pterostilbene was the more potent modulator of cognition and cellular stress, an effect the authors attributed to increased PPAR-α expression and greater lipophilicity. Importantly, this is a mouse model, not a human cognition trial.

Antioxidant and anti-inflammatory activity

Both upregulate endogenous antioxidant defences via Nrf2 signalling and dampen NF-κB-driven inflammatory transcription in preclinical models. Pterostilbene is generally the more potent of the two in cell-based assays, which is consistent with its greater cellular uptake. Similar antioxidant-versus-senolytic distinctions come up when comparing other polyphenols — see fisetin vs quercetin.

Human clinical evidence compared

This is the section that should carry the most weight in your decision, and it is the section most supplement marketing skips.

Resveratrol in human trials

Cognition and cerebrovascular function

The strongest single trial is the RESHAW study, published in Clinical Nutrition in 2021. It was a 24-month randomised, double-blind, placebo-controlled crossover trial in 125 postmenopausal women aged 45–85, who took 75 mg trans-resveratrol twice daily (150 mg/day) for 12 months and then crossed over. The trial reported significant improvements in overall cognitive performance and cerebrovascular function versus placebo, with benefits sustained over the two-year period. Verbal memory improvement was most apparent in women over 65.

This is a real, well-designed, long-duration trial — but note the population. It is a postmenopausal cohort, and resveratrol has phyto-oestrogenic properties, so the result may not generalise to men or younger women. Not every resveratrol cognition trial has been positive; a 26-week trial of 200 mg/day in healthy older adults found no significant effect on verbal memory or hippocampal measures.

Metabolic and cardiovascular markers

A 2020 meta-analysis in Molecules pooled five randomised controlled trials involving 388 participants with type 2 diabetes already on hypoglycaemic therapy. Resveratrol supplementation significantly lowered systolic blood pressure, although the effects on fasting glucose and insulin did not reach statistical significance. Heterogeneity between trials was substantial, so the finding should be treated as suggestive rather than settled.

Where resveratrol has clearly disappointed

The most important negative study is Semba and colleagues' 2014 analysis in JAMA Internal Medicine, drawn from the InCHIANTI cohort in Italy. Across 783 community-dwelling adults aged 65 and over, followed for nine years, 24-hour urinary resveratrol metabolite concentrations showed no association with inflammatory markers, cardiovascular disease, cancer, or all-cause mortality.

The important caveat is scope: this measured resveratrol achieved through a normal Western diet, not supplementation, and the cohort excluded supplement users. It does not prove supplements are useless. It does demolish the popular "red wine is why Mediterranean populations live longer" narrative.

Pterostilbene in human trials

The Riche trial: blood pressure down, LDL up

Essentially all standalone human efficacy data on pterostilbene comes from a single trial run at the University of Mississippi and published in Evidence-Based Complementary and Alternative Medicine in 2014 (registered as NCT01267227). Eighty adults with a total cholesterol of at least 200 mg/dL and/or LDL of at least 100 mg/dL were randomised into four groups for 6–8 weeks:

• Pterostilbene 125 mg twice daily (250 mg/day)
• Pterostilbene 50 mg twice daily (100 mg/day)
• Pterostilbene 50 mg plus grape extract 100 mg twice daily
• Matching placebo twice daily

The high-dose group saw systolic blood pressure fall by 7.8 mmHg (P < 0.01) and diastolic by 7.3 mmHg (P < 0.001). That is a clinically meaningful reduction, comparable in size to a low-dose antihypertensive.

However, the same trial found that pterostilbene monotherapy increased LDL cholesterol by 17.1 mg/dL (P = 0.001). That increase was not seen when pterostilbene was combined with grape extract, and appeared to be attenuated in participants already taking cholesterol medication. Participants not on cholesterol medication showed a small reduction in BMI.

The safety analysis from the same cohort

A separate 2013 safety publication from the same 80-patient cohort reported no adverse drug reactions on hepatic, renal or glucose markers by biochemical analysis, with 91.3% of participants completing the trial. On that basis, pterostilbene is generally described as safe at doses up to 250 mg/day for 6–8 weeks. Note the duration: that is a two-month dataset, not a long-term one.

Combination with nicotinamide riboside

Most human pterostilbene exposure in clinical research has come as part of NRPT — 250 mg nicotinamide riboside plus 50 mg pterostilbene, commercially known as Basis. In a randomised, double-blind, placebo-controlled trial in 120 healthy adults aged 60–80, published in npj Aging and Mechanisms of Disease in 2017, the recommended dose raised whole-blood NAD⁺ by approximately 40% at four and eight weeks, and the double dose by approximately 90%, with no change in the placebo group.

Two things to hold in mind. First, NAD⁺ elevation is a biomarker, not an outcome. Second, the NAD⁺ rise is attributable to the nicotinamide riboside, not the pterostilbene. We break this formula down in our Elysium Basis review, and cover the other major pterostilbene-containing formula in our NOVOS Core review.

Safety, side effects and drug interactions

Resveratrol safety profile

The European Food Safety Authority assessed synthetic trans-resveratrol at ≥99% purity and concluded that an intake of 150 mg/day for adults does not raise safety concerns. EFSA also noted that diarrhoea and other gastrointestinal symptoms were reported in uncontrolled intervention studies at doses of 1 g/day or higher.

The more clinically significant issue is drug interaction. Resveratrol inhibits several cytochrome P450 enzymes, including CYP3A4, CYP2C9 and CYP2D6, and is a weak inducer of CYP1A2. In practice this means it has the potential to alter blood levels of a wide range of medicines, including some anticoagulants, statins, calcium channel blockers, immunosuppressants and antidepressants. It also has antiplatelet activity, which compounds bleeding risk with warfarin, DOACs, aspirin or clopidogrel. EFSA specifically required that labels carry a statement that people taking medicines should only consume the product under medical supervision.

Pterostilbene safety profile

Short-term human safety data is reassuring on liver, kidney and glucose markers, but the dataset is small — effectively one cohort of 80 people for 6–8 weeks, plus combination-product trials. The LDL cholesterol signal described above is the main flag. Some users report increased appetite. Long-term safety data at supplemental doses does not exist.

Who should avoid both compounds

• Anyone who is pregnant, trying to conceive, or breastfeeding. Neither compound is authorised for these groups and safety data is absent.
• Anyone under 18.
• Anyone taking anticoagulant or antiplatelet medication, without specialist advice.
• Anyone with a hormone-sensitive condition (including oestrogen receptor-positive breast cancer), given resveratrol's phyto-oestrogenic activity, without oncology input.
• Anyone scheduled for surgery within two weeks, because of bleeding risk.
• Anyone with uncontrolled hyperlipidaemia should be cautious specifically with pterostilbene.

If you take any prescription medication, speak to your GP or pharmacist before starting either supplement. Your pharmacist can check for interactions in seconds and this is exactly what they are there for.

UK and EU regulatory status — the part most articles miss

This is where the two compounds part company most decisively for a UK buyer, and it is genuinely important.

Resveratrol: authorised, with a hard dose ceiling

Trans-resveratrol was authorised as a novel food ingredient by Commission Implementing Decision (EU) 2016/1190, following a favourable EFSA safety opinion. The conditions of use are specific: food supplements in capsule or tablet form, intended for the adult population only, at a maximum dose of 150 mg per day. Labels must state that people using medicines should only consume the product under medical supervision. Great Britain retained this authorisation, and it appears on the Food Standards Agency's GB register of authorised novel foods.

The practical implication: if a UK retailer is selling 500 mg or 1,000 mg resveratrol capsules, that product is being sold outside the authorised conditions of use. That does not necessarily make it dangerous, but it is a meaningful signal about how carefully that brand reads regulation.

Pterostilbene: assessed as novel, and not authorised in the EU

In January 2026 the European Commission updated its Novel Food Catalogue with decisions on several botanical actives. Purified pterostilbene extract (≥99%) from Pterocarpus santalinus was assessed as novel and not authorised for use in food or food supplements unless a pre-market novel food authorisation is granted. The same determination applied to purified apigenin and cycloastragenol.

Great Britain operates its own novel foods register and its own authorisation route through the FSA, so GB status is assessed separately from the EU catalogue and can differ. Because this is a fast-moving area, check the current FSA position before purchasing, and treat any UK seller making firm claims about pterostilbene's legal status with healthy scepticism. Regulatory awareness is one of the clearest markers of a serious supplement brand — the same logic we apply in our guide to third-party tested supplements.

Dosage, timing and absorption

Resveratrol dosing

In the UK and EU, 150 mg/day is the authorised adult ceiling for supplements, and it is also the dose used in the 24-month RESHAW cognition trial. Split dosing (75 mg twice daily) mirrors the trial protocol and helps offset the short plasma half-life. Look for products specifying trans-resveratrol content rather than total "resveratrol" or a percentage of a knotweed extract.

Pterostilbene dosing

Most formulas use 50–100 mg/day, which is the dose range that appears in combination products. The 250 mg/day used in the Riche trial is the dose that produced both the blood pressure benefit and the LDL increase. Given the lipid signal and the very limited long-term data, the lower end of the range is the more defensible starting point.

Timing and food

Both compounds are fat-soluble, so absorption is improved by taking them with a meal containing some dietary fat. This is the opposite of the advice for many NAD⁺ precursors — see our discussion of which supplements to take on an empty stomach and our guide to when to take NMN if you are building a full daily schedule.

Neither compound is a stimulant, so timing is flexible. Morning dosing with breakfast is the most common approach and easiest to stick to.

Which one should you choose?

Choose resveratrol if…

• You want the compound with the largest human evidence base, however mixed that evidence is.
• You are a postmenopausal woman interested in the cognitive and cerebrovascular findings.
• You want a clearly authorised UK novel food with a defined safe dose.
• Your LDL cholesterol is raised, or you have not had it measured recently.
• You are cost-sensitive. Resveratrol is a commodity ingredient and much cheaper per milligram — relevant if you are building a longevity stack on a budget.

Choose pterostilbene if…

• Absorption matters most to you and you are comfortable extrapolating from animal pharmacokinetics.
• You have recent, normal lipid results and are willing to retest after 12 weeks.
• You are specifically interested in the neuroprotective and PPAR-α preclinical findings.
• You are already using an NR-based formula in which pterostilbene is the standard partner ingredient.

Can you take both together?

There is no established interaction between the two and some commercial formulas include both. However, there is no human trial testing the combination, so any claimed synergy is theoretical. If you do combine them, keep resveratrol at or below 150 mg/day and pterostilbene at the low end, and monitor lipids. In most cases picking one and taking it consistently for three to six months is a more sensible experiment than adding both at once — you cannot attribute an effect to anything if you change three variables simultaneously.

Stacking stilbenes with NMN, NR and other longevity compounds

The most common reason people buy a stilbene is to pair it with an NAD⁺ precursor. The logic runs: sirtuins need NAD⁺ to function, stilbenes are proposed sirtuin modulators, so supplying the substrate and the activator together should be better than either alone.

That logic is plausible and untested in humans. What has been tested is that NAD⁺ precursors raise blood NAD⁺ reliably — see our complete NMN guide. If you want to build this stack, the practical starting point is a well-specified NAD⁺ precursor from the Welzo NMN collection, such as NMN Pro 1000, with a stilbene layered in afterwards rather than on day one.

A few related reads if you are designing a full protocol:

• The classic three-compound approach is covered in our NMN, TMG and resveratrol stack guide.
• For a different mitochondrial angle, compare urolithin A vs NMN.
• If you want to know what a realistic UK protocol costs, see longevity stack cost in the UK.
• To measure whether any of it is doing anything, read about biological age testing and set a baseline before you start.

How to judge product quality

Stilbene supplements vary enormously in quality, and the label rarely tells you what you need to know. Apply these checks:

• Isomer specificity. The label should say trans-resveratrol with a milligram figure, not "resveratrol 50% extract". Cis-resveratrol is far less studied and forms on light exposure.
• Purity specification. Pharmaceutical-grade material is typically ≥98% or ≥99%. Cheaper knotweed extracts standardised to 50% carry more plant matrix, including emodin, which is a laxative.
• A current certificate of analysis. Batch-specific, from an independent laboratory, covering identity, purity and heavy metals. Our guide to reading a supplement certificate of analysis walks through what each section means.
• Dose within legal limits. For resveratrol in the UK, 150 mg/day is the authorised ceiling. A 1,000 mg capsule is a red flag, not a bargain.
• Opaque, airtight packaging. Stilbenes are light-sensitive and oxidise. Clear plastic tubs are a formulation shortcut.
• Sensible excipients. Check what else is in the capsule — see supplement fillers explained.

If a brand cannot supply a batch COA on request, buy from one that can. For a broader framework on which longevity compounds are worth the money at all, see our longevity supplements guide and our honest assessment of category hype in is NMN a scam?

The bottom line on resveratrol vs pterostilbene

Pterostilbene wins decisively on pharmacokinetics. Resveratrol wins decisively on the volume and duration of human trial evidence, and on regulatory clarity in the UK. Pterostilbene carries one specific, replicated-in-principle-but-not-in-practice safety flag around LDL cholesterol that deserves genuine attention rather than the footnote it usually receives.

Neither compound has been shown to extend human lifespan, reverse ageing, or produce effects comparable to the fundamentals: regular resistance and aerobic exercise, adequate sleep, a diet built around whole foods, not smoking, and keeping blood pressure and lipids in a healthy range. Stilbenes are, at absolute best, a marginal addition on top of those. Treat any product marketed as a shortcut past them with suspicion.

If you want to start somewhere with better evidential footing, the NAD⁺ precursor category is the more established entry point — begin with the NMN pillar guide and the Welzo NMN supplements collection.

Frequently asked questions

Is pterostilbene better than resveratrol?

Pterostilbene is better absorbed — roughly 80% oral bioavailability versus roughly 20% for resveratrol in equimolar animal dosing. But "better absorbed" is not the same as "better for you". Resveratrol has a far larger human trial base, including a 24-month cognition trial, and pterostilbene has a documented LDL cholesterol signal. Neither is definitively superior.

Can you take resveratrol and pterostilbene together?

There is no known interaction and some commercial formulas include both. However, no human trial has tested the combination, so any synergy is theoretical. If combining, stay at or below 150 mg/day resveratrol and 50–100 mg/day pterostilbene, and check your lipids.

Does pterostilbene raise cholesterol?

In the main human trial, pterostilbene monotherapy increased LDL cholesterol by 17.1 mg/dL over 6–8 weeks in adults with pre-existing hypercholesterolaemia. The increase was not seen when pterostilbene was combined with grape extract, and appeared attenuated in people already on cholesterol medication. It has not been replicated in a large independent trial. If you have raised LDL or cardiovascular risk, discuss it with your GP first.

What is the correct resveratrol dosage in the UK?

Trans-resveratrol is authorised as a novel food for adults in capsule or tablet form at a maximum of 150 mg per day. That is also the dose used in the longest positive cognition trial. It is not authorised for under-18s, or for pregnant or breastfeeding women.

Is pterostilbene legal to sell in the UK?

In January 2026 the European Commission's Novel Food Catalogue confirmed that purified pterostilbene extract (≥99%) is novel and not authorised in the EU without a pre-market novel food authorisation. Great Britain maintains a separate register administered by the Food Standards Agency, so GB status is determined independently and can differ. Check the current FSA novel foods register before purchasing.

How long does it take for resveratrol or pterostilbene to work?

Neither produces a noticeable acute effect. In trials, blood pressure changes with pterostilbene emerged over 6–8 weeks, and cognitive changes with resveratrol were measured at 12 and 24 months. Judge them on measurable markers over three to six months, not on how you feel next week. See our guide on how long supplements take to work.

Should I take resveratrol or pterostilbene with food?

With food. Both are fat-soluble, so a meal containing some dietary fat improves absorption. Splitting resveratrol into two 75 mg doses mirrors the trial protocol and offsets its short plasma half-life.

Do resveratrol or pterostilbene interact with medications?

Resveratrol inhibits several cytochrome P450 enzymes and has antiplatelet activity, so it can interact with anticoagulants, some statins, calcium channel blockers, immunosuppressants and antidepressants. EFSA specifically requires labels to warn that people on medicines should only use it under medical supervision. Pterostilbene's interaction profile is less well characterised, which is itself a reason for caution. Always check with your GP or pharmacist.

Does resveratrol actually extend lifespan in humans?

No. There is no human lifespan evidence. The nine-year InCHIANTI cohort study of 783 older adults found that dietary resveratrol exposure was not associated with reduced mortality, cardiovascular disease, cancer, or inflammatory markers. Lifespan extension has been observed in some simple organisms and in mice on high-calorie diets, which is not the same thing.

Which is better for brain health, resveratrol or pterostilbene?

Pterostilbene crosses the blood–brain barrier more readily and outperformed resveratrol in an accelerated-ageing mouse model. But there are no standalone human cognition trials for pterostilbene, whereas resveratrol has a 24-month randomised human trial showing cognitive and cerebrovascular improvement in postmenopausal women. On current human evidence, resveratrol is the better-supported choice for brain health.

References

1. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol. 2011;68(3):593–601. https://pubmed.ncbi.nlm.nih.gov/21116625/
2. Riche DM, Riche KD, Blackshear CT, et al. Pterostilbene on metabolic parameters: a randomized, double-blind, and placebo-controlled trial. Evid Based Complement Alternat Med. 2014;2014:459165. https://pmc.ncbi.nlm.nih.gov/articles/PMC4099343/
3. Riche DM, McEwen CL, Riche KD, et al. Analysis of safety from a human clinical trial with pterostilbene. J Toxicol. 2013;2013:463595. https://pmc.ncbi.nlm.nih.gov/articles/PMC3575612/
4. Thaung Zaw JJ, Howe PRC, Wong RHX. Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: a 24-month randomised, double-blind, placebo-controlled, crossover study. Clin Nutr. 2021;40(3):820–829. https://pubmed.ncbi.nlm.nih.gov/32900519/
5. Semba RD, Ferrucci L, Bartali B, et al. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern Med. 2014;174(7):1077–1084. https://pubmed.ncbi.nlm.nih.gov/24819981/
6. Dellinger RW, Santos SR, Morris M, et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD⁺ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. npj Aging Mech Dis. 2017;3:17. https://www.nature.com/articles/s41514-017-0016-9
7. EFSA Panel on Dietetic Products, Nutrition and Allergies. Safety of synthetic trans-resveratrol as a novel food pursuant to Regulation (EC) No 258/97. EFSA Journal. 2016;14(1):4368. https://efsa.onlinelibrary.wiley.com/doi/abs/10.2903/j.efsa.2016.4368
8. European Commission. Commission Implementing Decision (EU) 2016/1190 authorising the placing on the market of trans-resveratrol as a novel food ingredient. Official Journal of the European Union, L 196, 21 July 2016. https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32016D1190
9. Food Standards Agency. Novel foods authorisation guidance and the GB register of authorised novel foods. https://www.food.gov.uk/business-guidance/regulated-products/novel-foods-guidance
10. Hancocks N. Novel Foods: major updates on botanical assessments. NutraIngredients, 27 January 2026. https://www.nutraingredients.com/Article/2026/01/27/novel-foods-major-updates-on-botanical-assessments/
11. Linus Pauling Institute Micronutrient Information Center. Resveratrol. Oregon State University. https://lpi.oregonstate.edu/mic/dietary-factors/phytochemicals/resveratrol
12. Chang J, Rimando A, Pallas M, et al. Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiol Aging. 2012;33(9):2062–2071. https://www.sciencedirect.com/science/article/abs/pii/S019745801100337X
13. Nyambuya TM, Nkambule BB, Mazibuko-Mbeje SE, et al. A meta-analysis of the impact of resveratrol supplementation on markers of renal function and blood pressure in type 2 diabetic patients on hypoglycemic therapy. Molecules. 2020;25(23):5645. https://pmc.ncbi.nlm.nih.gov/articles/PMC7730696/
14. Chan EWC, Wong CW, Tan YH, et al. Resveratrol and pterostilbene: a comparative overview of their chemistry, biosynthesis, plant sources and pharmacological properties. J Appl Pharm Sci. 2019;9(7):124–129. https://www.japsonline.com/abstract.php?article_id=2952&sts=2
15. Dellinger RW, Holmes HE, Hu-Seliger T, et al. Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: a double-blind, placebo-controlled clinical trial. Hepatology. 2023;78(1):225–242. https://onlinelibrary.wiley.com/doi/full/10.1002/hep.32778
16. National Center for Biotechnology Information. PubChem Compound Summary: Pterostilbene. https://pubchem.ncbi.nlm.nih.gov/compound/5281727